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Abstract
Background Cognitive impairment (CI) affects approximately one-third of the patients with early multiple sclerosis (MS) 
and clinically isolated syndrome (CIS). Little is known about factors predicting CI and progression after initial diagnosis.
Methods Neuropsychological screening data from baseline and 1-year follow-up of a prospective multicenter cohort study 
(NationMS) involving 1123 patients with newly diagnosed MS or CIS were analyzed. Employing linear multilevel models, 
we investigated whether demographic, clinical and conventional MRI markers at baseline were predictive for CI and longi-
tudinal cognitive changes.
Results At baseline, 22% of patients had CI (impairment in ≥2 cognitive domains) with highest frequencies and severity in 
processing speed and executive functions. Demographics (fewer years of academic education, higher age, male sex), clinical 
(EDSS, depressive symptoms) but no conventional MRI characteristics were linked to baseline CI. At follow-up, only 14% 
of patients showed CI suggesting effects of retesting. Neither baseline characteristics nor initiation of treatment between 
baseline and follow-up was able to predict cognitive changes within the follow-up period of 1 year.
Conclusions Identification of risk factors for short-term cognitive change in newly diagnosed MS or CIS is insufficient using 
only demographic, clinical and conventional MRI data. Change-sensitive, re-test reliable cognitive tests and more sophis-
ticated predictors need to be employed in future clinical trials and cohort studies of early-stage MS to improve prediction.
Keywords Multiple sclerosis · Cognition · Neuropsychology · Cohort study · Longitudinal
Introduction
Cognitive impairment (CI) and associated neurobehavioral 
symptoms (e.g., fatigue, depression) are frequent and often 
highly debilitating in multiple sclerosis (MS) [1]. Particu-
larly cognitive processing speed, executive functions such as 
working memory capacity as well as verbal and figural epi-
sodic memory show a disease-related decline with adverse 
effects on patient’s vocational status and quality of life [2, 3]. 
CI has been shown to be present in the earliest disease stages 
of MS as well as in clinically isolated syndrome (CIS) [4, 5]. 
Several studies suggest that CI can be present independent 
of physical disability and that its development and progres-
sion is most pronounced during the first years after disease 
onset [6, 7]. Despite its increasingly recognized clinical 
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relevance for patients with early MS, little is known about 
risk factors that contribute to CI, its short-term course and a 
potential progression after initial diagnosis of MS [3, 8, 9]. 
Associations between clinical disease severity markers (e.g., 
EDSS, number of relapses, disease duration), conventional 
MRI parameters of disease burden (e.g., number and/or site 
of lesions, degree of atrophy) and both severity and profiles 
of CI have been reported in large cross-sectional cohort stud-
ies on a group level [8, 10–12]. However, these associations 
were less evident in patients with early disease stages [13]. 
A range of studies have also investigated longitudinally risk 
factors and prediction of long-term outcome of CI in patients 
with MS mainly based on clinical and MRI parameters [5, 6, 
14–16]. Compatible with results from cross-sectional stud-
ies, baseline brain volume [14, 15] and to a lesser degree 
lesion metrics [6, 16] usually contribute to long-term pre-
diction of CI but predictive abilities were generally low 
and inconsistent for short-term follow-up periods and early 
disease stages [5, 14]. Both cross-sectional and longitudi-
nal studies, moreover, display a substantial heterogeneity 
regarding (i) assessments and definitions of CI, (ii) selection 
and measurement of predictor variables, (iii) homogeneity 
of sample characteristics (e.g., disease severity, intake of 
medication, etc.) and (iv) employed MRI techniques and 
length of follow-up periods. These methodological issues 
currently impede an integration and extrapolation of results 
onto individual cases with newly diagnosed MS [6, 8, 10, 
11, 14–17]. In turn, this gap in key-knowledge hinders incor-
poration of cognitive monitoring into standard clinical care 
which in turn hampers the development and evaluation of 
specific programs for the prevention and rehabilitation of 
CI in MS [1].
Here, we aimed to investigate whether CI and its short-
term progression can be effectively predicted by a single 
marker or combinations of conventional demographic, 
clinical and MRI parameters that are readily available to 
clinicians at the time of diagnosing MS. We were further 
interested in the relative importance of these potential risk 
factors both for CI as well as for its longitudinal change. To 
this end, we analyzed cognitive screening data from the Ger-
man National MS cohort (NationMS) of patients with initial 
diagnosis of either MS or CIS [18]. We assumed standard 
sociodemographic data, established clinical markers of MS 
disease burden and/or conventional MRI parameters at base-
line to be predictive for CI. We further analyzed whether 
changes in cognitive test performance during the first year 
after diagnosis may be effectively predicted using these 
baseline parameters.
Materials and methods
NationMS cohort study
The German National MS cohort is a prospective longitu-
dinal observational study comprising (a) detailed assess-
ment of patients with first diagnosis of MS or CIS and (b) 
yearly follow-up assessment with a standardized protocol 
across 22 centers in Germany. It was approved by the eth-
ics committee of Ruhr-University Bochum (Registration 
no. 3714-10), and consecutively, by all local committees 
of the participating centers. All patients provided written 
informed consent. Inclusion and exclusion criteria as well 
as assessment plans are laid out in detail elsewhere [18]. In 
short, inclusion required a recent diagnosis of either CIS or 
RRMS according to Barkhof [19] or 2005 McDonald [20] 
criteria, respectively; exclusion criteria implied previous 
intake of disease-modifying therapies (DMTs), other neu-
rological or psychiatric conditions as well as progressive 
courses of MS. Assessment involved sociodemographic 
data, detailed neurological status, medication status regard-
ing DMTs, standardized cranial MRI evaluation regarding 
signs of disease burden, collection of biomaterial as well 
as neuropsychological screenings and self-report question-
naires. Datasets from N = 1123 patients were included for 
baseline statistics. Data from N = 958 patients were available 
for follow-up assessment at an average of 12.13 (SD = 1.54) 
months after baseline.
Cognitive screening data
MUSIC: Multiple Sclerosis Inventory for Cognition
The MUSIC is a brief multiple-domain cognitive screening 
test geared towards rapid assessment of the most frequently 
impaired cognitive domains in MS [21]. It is widely used as 
a screening for CI in German-speaking countries and con-
sists of six subtests, in the following order: (1) Word List 
Learning (number of words learned over two consecutive 
trials out of a list with 10 words), (2) Interference Word List 
Learning (number of words learned from a 10 word inter-
ference list), (3) Category Fluency Switch Condition (num-
ber of correctly associated words within 1 min from two 
continuously alternating semantic categories), (4) Modified 
Stroop Task (speed of correctly naming animal silhouettes 
either in a congruent or incongruent condition with printed 
animal names on them), (5) Word List Recall (number of 
correctly recalled words from the initially learned word list 
after a short delay). For easier inter-test and inter-subject 
comparisons, individual test scores were z standardized 
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based on normative data from N = 158 German-speaking 
healthy young adults as laid out in detail elsewhere [21].
PASAT: Paced Auditory Serial Addition Test
The PASAT 3-s version is a widely used cognitive screen-
ing test in MS tapping into processing speed, divided 
attention and working memory. PASAT data were 
extracted from the Multiple Sclerosis Functional Compos-
ite (MSFC) [22]. Participants are asked to add numbers in 
a 1-back-like fashion during a continuous auditory pres-
entation (one number presented every 3 s) and verbally 
state the correct sums continuously. Outcome measure 
is the number of correct calculations during a fixed time 
period. Administration was carried out in accordance 
with the manual including a preceding training trial and 
the use of a parallel version at follow-up. Analogous to 
the MUSIC data, individual PASAT test scores were z 
standardized, stratified for age and education based on 
normative data from a German sample of N = 241 healthy 
controls [23].
Across all cognitive tests (i.e., subtests of MUSIC and 
PASAT), a normative z score of − 1.645 was used as a 
cut-off for “impaired performance” as this value approxi-
mately represents the 5th percentile rank. Following the 
criterion put forth by Amato et al., impaired performance 
in two or more subtests was required to classify individual 
patients as having CI [6]. Additionally, an unweighted 
mean z score of all cognitive tests was calculated for each 
patient as a proxy for overall severity of CI.
Prediction parameters
A priori-considered predictors for CI and longitudinal 
change are depicted in Table 1. Besides general sociode-
mographic factors known to influence cognitive status, we 
examined a range of previously discussed disease-specific 
risk factors for CI in MS [9]. In total, we considered 17 
predictor variables assessed at baseline pertaining to the 
domains demographics, clinical disease severity markers, 
MRI ratings of disease burden and self-reports on psycho-
pathology (depressive symptoms and fatigue).
Table 1  Baseline predictors 
and sample characteristics (total 
N = 1123)
CI cognitive impairment, EDSS Expanded Disability Status Scale, RRMS relapsing–remitting multiple 
sclerosis, CIS clinically isolated syndrome, DMT disease-modifying therapy, BDI Beck Depression Inven-
tory, FSMC Fatigue Scale for Motor and Cognitive functions
a N = 103 (9.6%) of patients had scores ≥ 19, the clinical cut-off score suggested for indicating an at least 
mild depressive episode in patients with MS
b N = 390 (36.3%) of patients had scores ≥ 42, indicating at least mild fatigue
Predictor Available N Mean (SD)
Demographic characteristics
Age, years 1123 34.12 (9.67)
Sex, m:w 1123 348:775
Education, years 1103 14.41 (2.57)
Clinical characteristics
Time since symptom onset, years 1123 0.57 (0.61)
EDSS 1120 1.49 (0.99)
Total number of relapses 958 1.39 (0.62)
Type of disease, RRMS:CIS 1123 622:501
Type of first relapse, mono-:polysymptomatic 1122 831:291
Start of DMT after baseline, yes:no 958 782:176
MRI characteristics
Number of T2 lesions 1117 7.67 (2.21)
Periventricular lesions, yes:no 1123 1081:42
Juxtacortical lesions, yes:no 1123 871:252
Infratentorial lesions, yes:no 1123 666:457
Black holes, yes:no 822 489:333
Visible atrophy, yes:no 877 97:780
Psychopathological characteristics
Depressive symptoms, BDI-II total 1077a 7.61 (7.72):185
Fatigue, FSMC total 1073b 39.12 (18.21):390
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Statistics
SPSS 25 (IBM Corporation) was used for data preparation 
and R 3.3.0 (R Foundation, Vienna, Austria) for statistical 
computations. Descriptive statistics (means and SD as well 
as frequencies (%) of impaired cases) for baseline and fol-
low-up cognitive data were computed. Change of CI from 
baseline to follow-up was evaluated using paired t tests. Lin-
ear multilevel models were applied to predict baseline cogni-
tive test values as well as baseline to follow-up changes in 
cognitive test values and to control for possible dependency 
between observations gathered in the same participating 
center. All predictors were entered into the multiple regres-
sion model simultaneously so that co-variance between pre-
dictors was controlled for. Models were fitted adopting a 
Bayesian multilevel approach with the brms package [24] 
using the probabilistic programming language Stan. For all 
analyses, a 5% significance level was used and Bonferroni 
correction was applied within each regression model (that is 
over 18 regression coefficients per model). Prior to analyses, 
dichotomous variables (e.g., sex, presence of brain atrophy) 
were dummy-coded to include them into the regression mod-
els. Missing values in predictor variables were imputed by 
means of 20-fold multiple imputation by chained equations 
using the mice package [25]. The full analysis is available 
within the Open Science Framework (https ://osf.io/wznca /).
Results
Frequencies of patients with and without CI are depicted in 
Fig. 1a for baseline and follow-up for each cognitive sub-
test/domain separately. At baseline, a total of 245 (22%) of 
patients were classified as having CI with the highest fre-
quencies observed in the interference subscore of the Modi-
fied Stroop Task (N = 185; 17%) of the MUSIC followed 
by the PASAT (N = 135, 12%). Other subtests (e.g., verbal 
learning and memory) were substantially less frequently 
impaired. At follow-up, the general profile of relatively fre-
quent impairments in processing speed and executive func-
tions compared to other cognitive domains was similar to 
baseline. However, substantially less frequent impairments 
were observed across all tests at follow-up (overall CI in 
N = 120; 14%).
Regarding the severity of deficits, normative z scores of 
baseline cognitive tests and significances of changes from 
baseline to follow-up are presented in Fig. 1b and Table 2.
Additionally, spaghetti plots depicting individual cogni-
tive changes from baseline to follow-up can be found in Sup-
plementary Figure 1 for each subtest.
Compared to normative data, the sample’s average over-
all cognitive ability was not pathological with a mean of 
all cognitive tests of z = − 0.06 at baseline. Compatible 
with frequency data, processing speed (PASAT, z = − 0.20) 
and executive functions (modified Stroop Test interference 
seconds, z = − 0.40) were the domains with the lowest per-
formances on average. At follow-up, patients performed 
significantly better on the mean cognitive z score (z = 0.16 
p < 0.0001). Likewise, significant gains from baseline to 
follow-up were observed in the majority of subtests with the 
exception of the Stroop Inhibition Quotient and the Learn-
ing trial of the Interference word list for which no change 
occurred.
Results of the multilevel linear regression models are 
presented for the mean z score of all cognitive tests repre-
senting a proxy for overall CI. Regression coefficients of the 
model including all predictors for baseline CI are provided 
in Table 3.
The proportion of variance explained by this model was 
R2 = 0.27 when including the variance explained by the par-
ticipating center and R2 = 0.21 without it. The predictors that 
remained significant after Bonferroni correction were age 
(“more CI in older patients”), years of education (“more 
CI in patients with fewer years of academic education”), 
EDSS score (“more CI in patients with higher EDSS”), 
BDI-II score (“more CI in patients with more self-reported 
depressive symptoms”), and sex (“more CI in males”). Other 
MS-specific clinical or MRI characteristics did not signifi-
cantly contribute to the prediction of baseline CI. Regres-
sion coefficients of the model including all predictors for 
the baseline to follow-up changes in cognitive test scores 
are provided in Table 4.
No predictor remained significant after Bonferroni cor-
rection indicating that longitudinal cognitive change could 
neither be effectively predicted by the considered baseline 
variables nor the additional variable of DMT initiation after 
baseline (yes vs. no). The proportion of variance explained 
was R2 = 0.06 when including the variance explained by par-
ticipating center and R2 = 0.05 without it. Likewise, results 
for each separate cognitive subtest were non-significant 
regarding the prediction of cognitive change from baseline 
to 1-year follow-up. These and other additional analyses are 
provided as supplementary material on https ://osf.io/wznca /.
Discussion
Despite the increasingly recognized burden of CI in MS, 
little is known about an increased individual risk for CI 
after initial diagnosis of MS, hampering research on early 
prevention and treatment. In the current study, we aimed to 
characterize CI and identify risk factors for its severity and 
short-term course in a large, clinically homogeneous cohort 
of patients with first diagnosis of MS or CIS. To this end, 
neuropsychological screening data from N = 1123 patients 
enrolled in the multicentric German National MS cohort 
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study were analyzed. We used linear multilevel regression 
models to predict CI and the short-term progression of CI 
from conventional MRI characteristics and other clinical and 
demographic parameters that are usually accessible to clini-
cians at the time of diagnosis.
Frequency, severity and profile of CI
Adopting conventional criteria of overall CI, we found 22% 
of patients to be impaired at baseline, with largest deficits 
in subtests for processing speed and executive function and 
lowest impairments in verbal learning and memory. The 
Fig. 1  a Frequencies of patients with overall CI (≥ 2 tests impaired 
compared to age- and education-corrected normative data) and of 
patients with impairments (z score <− 1.645) in single cognitive tests 
for baseline (BL) and follow-up (FU) assessments. b Mean normative 
z scores stratified for age and education for overall CI (mean z score 
of all tests) and for each cognitive test separately for baseline (BL, 
left) and follow-up (FU, right)
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Table 2  Mean (SD) of unstandardized raw scores and mean normative z scores of cognitive tests for baseline, follow-up and longitudinal change
MUSIC subscores as well as PASAT test scores and corresponding normative z scores for baseline and follow-up
MUSIC multiple sclerosis inventory for cognition, Max maximum raw score, CI cognitive impairment, N/A not applicable, PASAT paced audi-
tory serial addition test, pBon Bonferroni-corrected p value for paired t test of baseline vs. follow-up mean scores
Cognitive test N Baseline Follow-up Longitudinal change
Raw mean (SD) Mean z (SD) N Raw mean (SD) Mean z (SD) Raw change (SD) pBon
Word list learning (max 20) 1067 15 (3) 0.23 (1.26) 913 16 (3) 0.61 (1.18) 0.81 (2.70) < 0.001
Interference list (max 10) 1067 6 (2) 0.42 (0.99) 913 6 (2) 0.49 (1.01) 0.13 (1.70) 0.028
Word list free recall (max 10) 1065 6 (2) 0.03 (1.23) 913 7 (2) 0.42 (1.21) 0.74 (2.16) < 0.001
Category fluency switch 1067 15 (5) − 0.06 (0.86) 913 15 (5) 0.08 (0.88) 0.77 (4.82) < 0.001
Stroop naming speed seconds 1066 22 (5) − 0.20 (1.55) 910 21 (5) − 0.05 (1.56) − 0.55 (4.51) < 0.001
Stroop interference seconds 1066 28.6 (8.3) − 0.40 (1.69) 910 27.6 (7.9) − 0.20 (1.61) − 1.12 (7.81) < 0.001
Stroop inhibition quotient 1066 7 (6) − 0.34 (1.42) 910 6 (5) − 0.22 (1.20) − 0.57 (6.70) 0.012
MUSIC total score (max 32) 1067 25 (5) N/A 913 26 (4) N/A 1.02 (3.87) < 0.001
PASAT 3 s (max 60) 1038 46 (11) − 0.20 (1.11) 876 49 (11) 0.10 (1.05) 2.75 (9.10) < 0.001
Overall CI (mean z of all 
tests)
1038 N/A − 0.06 921 N/A 0.16 0.21 (0.67) < 0.001
Table 3  Regression coefficients 
for baseline mean cognitive test 
scores
Coefficients in bold indicate a significant influence on the outcome variable (mean z of cognitive test per-
formance at baseline). Negative regression coefficients indicate that larger values in the predictor have a 
negative influence on the outcome variable and vice versa
b regression coefficient, SE standard error, l95% CI lower bound of the 95% credible interval, u95% CI 
upper bound of the 95% credible interval, p uncorrected two-sided p value, pBon Bonferroni corrected two-
sided p value
a Dichotomous variables that have been dummy-coded prior to analysis
Coefficient b SE l95% CI u95% CI p pBon
Intercept − 0.267 0.162 − 0.585 0.050 0.098 –
Demographic characteristics
Age − 0.148 0.023 − 0.193 − 0.103 0.000 0.000
Sex (female vs. male)a 0.279 0.047 0.186 0.372 0.000 0.000
Education, years 0.188 0.023 0.144 0.233 0.000 0.000
Clinical characteristics
Years since symptom onset − 0.012 0.026 − 0.063 0.039 0.637 1.000
EDSS − 0.112 0.025 − 0.161 − 0.064 0.000 0.000
Total number of relapses 0.040 0.047 − 0.052 0.133 0.399 1.000
Type of disease (RRMS vs. CIS)a 0.064 0.051 − 0.036 0.166 0.214 1.000
Type of 1st relapse (poly- vs. 
monosymptomatic)a
− 0.046 0.051 − 0.145 0.053 0.368 1.000
Start of DMT after  baselinea 0.079 0.061 − 0.041 0.200 0.196 1.000
MRI characteristics
Number of T2 lesions − 0.045 0.022 − 0.088 − 0.002 0.040 0.681
Periventricular lesions  presenta 0.018 0.116 − 0.208 0.247 0.877 1.000
Juxtacortical lesions  presenta − 0.051 0.054 − 0.156 0.055 0.345 1.000
Infratentorial lesions  presenta − 0.059 0.044 − 0.144 0.027 0.175 1.000
Black holes  presenta − 0.013 0.056 − 0.123 0.097 0.823 1.000
Visible atrophy  presenta − 0.094 0.075 − 0.241 0.049 0.209 1.000
Psychopathological characteristics
Depressive symptoms (BDI-II) − 0.111 0.031 − 0.170 − 0.050 0.000 0.006
Fatigue (FSMC total) 0.006 0.031 − 0.056 0.067 0.853 1.000
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result of a relatively larger impairment in attention and pro-
cessing speed as compared to other cognitive domains is 
well in line with previous studies on the cognitive profile 
of patients with early MS [6, 8] and CIS [1, 3]. Overall fre-
quency and mean severity of CI was lower in our sample 
than commonly reported: the majority of previous studies 
found approximately one-third of patients with CI in early 
MS or CIS [3, 6, 7], although reported frequencies range 
from < 15 to > 50% [5, 26]. One explanation for this dis-
crepancy may be that the current sample is unique in terms 
of a homogeneous sample in a very early disease stage with 
a median disease duration of only 0.33 years [18]. Compen-
satory mechanisms such as cognitive reserve may attenuate 
direct measurability of CI specifically in young patients with 
low overall disease burden and high formal education result-
ing in lower frequencies [17]. Hence, patients with larger 
cognitive reserve capacity may be able to compensate for 
brain pathology despite suffering from clinically relevant 
CI [13]. An additional explanation for our finding of a lower 
prevalence of CI in patients with early MS and CIS may be 
that the employed screening tests are less sensitive to detect 
CI in these early disease stages that might extend beyond 
executive and speed-related domains. Reports on the preva-
lence of CI in MS depends on (a) the employed tests (e.g., 
screening tests only or extensive test batteries), (b) the for-
mal definition of CI (e.g., one or two standard deviations 
below the norm; comparison to a control group), and (c) the 
composition of the sample (e.g., patients with progressive 
MS show a different degree of CI than patients with early 
MS or CIS [27]). Internationally accepted standards regard-
ing screening for CI have been proposed in terms of the 
Brief International Cognitive Assessment in MS (BICAMS 
battery) and may allow a higher sensitivity to detect relevant 
CI in MS throughout the different disease stages [28]. For 
instance, the Symbol Digit Modalities Test (SDMT) has 
been shown to be a more reliable, and sensitive measure of 
cognitive processing speed than the PASAT employed in this 
study [29, 30]. More specific cognitive functions like calcu-
lation skills may as well influence individual PASAT results. 
Thus, while the Modified Stroop Task of the MUSIC was 
Table 4  Regression coefficients 
for baseline to follow-up 
changes in mean cognitive test 
scores
Coefficients in bold indicate a significant influence on the outcome variable (mean z of baseline to follow-
up change of cognitive test performance). Negative regression coefficients indicate that a larger value in the 
predictor has a negative influence on the outcome variable and vice versa
b regression coefficient, SE standard error, l95% CI lower bound of the 95% credible interval, u95% CI 
upper bound of the 95% credible interval, p uncorrected two-sided p value, pBon Bonferroni corrected two-
sided p value
a Dichotomous variables that have been dummy coded prior to analysis
Coefficient b SE l95% CI u95% CI p pBon
Intercept − 0.273 0.228 − 0.723 0.174 0.234 –
Demographic characteristics
Age − 0.073 0.035 − 0.141 − 0.005 0.034 0.580
Sex (female vs. male)a 0.141 0.072 0.001 0.283 0.049 0.826
Education (years) − 0.031 0.035 − 0.099 0.036 0.372 1.000
Clinical characteristics
Years since symptom onset 0.044 0.040 − 0.034 0.124 0.266 1.000
EDSS 0.086 0.037 0.013 0.157 0.022 0.370
Total number of relapses − 0.045 0.066 − 0.176 0.085 0.497 1.000
Type of disease (RRMS vs. CIS)a − 0.037 0.079 − 0.192 0.117 0.642 1.000
Type of 1st relapse (poly- vs. 
monosymptomatic)a
0.106 0.077 − 0.044 0.258 0.173 1.000
Start of DMT after baseline a − 0.125 0.088 − 0.299 0.048 0.158 1.000
MRI characteristics
Number of T2 lesions − 0.006 0.034 − 0.072 0.059 0.850 1.000
Periventricular lesions  presenta 0.211 0.176 − 0.134 0.553 0.231 1.000
Juxtacortical lesions  presenta 0.149 0.083 − 0.015 0.311 0.076 1.000
Infratentorial lesions  presenta 0.072 0.068 − 0.061 0.204 0.294 1.000
Black holes  presenta − 0.114 0.087 − 0.286 0.055 0.188 1.000
Visible atrophy  presenta 0.124 0.113 − 0.093 0.348 0.271 1.000
Psychopathological characteristics
Depressive symptoms (BDI-II) 0.080 0.051 − 0.020 0.181 0.118 1.000
Fatigue (FSMC total) − 0.106 0.053 − 0.212 − 0.003 0.042 0.715
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able to detect early deficits in processing speed and execu-
tive function, the single-trial ten-item list might be insuffi-
cient to reveal subtle memory changes that might unfold in 
a multiple-trial learning-paradigm.
Predictors of CI and its progression
We found baseline CI to be significantly associated with 
three general demographic characteristics: male sex, fewer 
years of education and higher age. These factors have previ-
ously been linked to lower (verbal-)cognitive test perfor-
mance in healthy adults suggesting influences that are not 
specific to MS or CIS but may, nevertheless, be of clini-
cal importance for the interpretation of MS patients’ test 
performances [31, 32]. Considering MS-specific clinical 
characteristics, only EDSS (a marker for mainly physical 
disease burden) and severity of depressive symptoms (BDI-
II) were associated with severity of CI at baseline. These 
results are in line with previous evidence from large patient 
samples finding that higher EDSS and depressive symptoms 
negatively influence cognitive status [10, 27, 33]. Surpris-
ingly, none of the conventional MRI (e.g., visual inspection 
of atrophy, number of T2 lesions) or other clinical predictors 
(e.g., type of disease CIS/RRMS, total number of relapses) 
that have previously been directly linked to CI and its long-
term course contributed to prediction. This result may again 
cast doubts on the sensitivity of the employed screening tests 
to reliably detect CI in early disease stages. In the current 
sample, however, brain pathology and disease severity were 
also homogeneously low and relationships between CI and 
conventional markers for structural brain damage may be 
generally weak in early MS, even when using more sophis-
ticated neuropsychological assessments. In a recent large 
cohort study, lack of association between brain pathology 
(as measured by voxel-based morphometry) and perfor-
mance in the BICAMS test battery was termed a “clin-
ico-radiological paradox” and attributed to both, stronger 
compensatory mechanisms (e.g., cognitive reserve) and a 
statistical restriction of range within a homogeneous sample 
of patients in early disease stages [13]. Despite the large 
sample size and the numerous considered clinical, demo-
graphic and conventional MRI baseline parameters as well 
as the variable of DMT initation after baseline, the longi-
tudinal change of cognition over the course of 1 year could 
not be sufficiently predicted. One explanation may be that, 
for instance, for the considered MRI parameters and DMT 
initiation, the categorization was too broad (e.g., dichoto-
mization DMT start yes vs. no, visible MRI atrophy yes vs. 
no). On the other hand, the follow-up interval of 1 year may 
be too short to detect clinically relevant changes. However, 
significant gains in cognitive performance were observed in 
the majority of patients and in most cognitive subtests. This 
strongly suggests that test performances in both, MUSIC and 
PASAT, were substantially influenced by practice effects, 
potentially masking clinically relevant longitudinal changes 
after 1 year. A recent review has estimated the average effect 
size of cognitive retesting in a 12-month interval to be as 
high as 0.25 while some standard neuropsychological tests 
reached effect sizes of 0.73 [34]. Likewise in patients with 
MS, carryover effects from one testing session to another is 
a frequent problem in longitudinal test designs and common 
to a range of neuropsychological tests including the PASAT 
and to lesser degrees also the SDMT [29, 35, 36]. Although 
alternate test versions matched for difficulty and modern 
regression-based normative data (including estimates for 
retesting effect-sizes) may attenuate the influence of prac-
tice effects, few standardized cognitive tests employed in 
testing patients with early MS provide these features. Moreo-
ver, despite the use of an alternate version in the PASAT in 
this study, patients on average performed significantly bet-
ter at follow-up, highlighting a likely influence of familiar-
ity that is not dependent on the particular stimuli. Practice 
effects may endure for approximately 1 year after a baseline 
assessment and are most pronounced between the first and 
second evaluations [37, 38]. This is, particularly, true for 
tests assessing memory, learning and executive functions 
while visuo-perceptive tasks are less prone to practice effects 
[39]. Hence, the difference of some cognitive tests in their 
resilience against practice effects has to be considered more 
rigorously when planning re-evaluation schedules. Moreo-
ver, additional cognitive testing (performed outside of the 
study or by patient self-assessment and training) needs to 
be controlled for.
Conclusions
In patients first diagnosed with MS or CIS, demographic 
characteristics (male sex, higher age, lower education) as 
well as more severe depressive symptoms (BDI-II) and 
higher physical disability (EDSS) are significantly asso-
ciated with severity of CI. In patients with these charac-
teristics, neuropsychological monitoring and potentially 
cognitive rehabilitation should be considered. No other dis-
ease-specific clinical or conventional MRI parameters from 
clinical routine were significantly related to the presence of 
CI in this large cohort of patients in earliest disease stages. 
Moreover, longitudinal prediction of short-term cognitive 
change over the course of 1 year was insufficient despite the 
large number of patients and the inclusion of numerous con-
ventional yet disease-specific and previously discussed pre-
dictor variables. These findings indicate that three branches 
of research are highly needed to increase our understanding 
of CI, its clinical relevance and its risk factors in early MS to 
blaze the trail for early interventions: (1) establishment and 
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evidence-based proof of sensitive and change-sensitive cog-
nitive outcome parameters providing free-to-use longitudinal 
normative data. (2) Evidence that these assessments are able 
to detect disease-specific and clinically relevant CI (i.e., by 
validation with patient-centered outcomes) from the earliest 
to advanced disease stages. (3) Improving the prediction of 
these measurements by the development of refined clinical 
scales and standardized automation of MRI parameters for 
use in clinical routine [40].
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